Effect of miR-21 on apoptosis in hepatoblastoma cell through activating ASPP2/p38 signaling pathway in vitro and in vivo
Source abstract
Abstract
The objective of this study was to investigate the mechanism underlying miR-21-associated apoptosis in HB. In this study, HB and adjacent tissues were collected from patients with HB. RT-PCR, FISH, western blot, apoptosis assay, migration, invasion and wound healing assays, caspase activity assay, luciferase reporter assays, and xenografts mouse model were used to determine the effects of miR-21 on HB cell apoptosis. The results revealed that miR-21 was up-regulated in both HB cell and tissue and was associated with progression of HB. MiR-21 inhibitor enhanced the apoptosis level in HB cells. MiR-21 inhibitor showed reduced abilities of migration and invasion. ASPP2 was a target gene of miR-21. Inhibition of ASPP2 increased abilities of migration and invasion in HB cells. Furthermore, miR-21 inhibitor caused increased activity p-38 signaling. In a xenografts mouse model, miR-21 inhibitor could significantly suppress tumor growth in nude mice along with enhanced expressions of ASPP2 and p38. Taken together, the results suggest that upregulation of miR-21 is related to HB progression and miR-21-associated apoptosis in HB is mediated through ASPP2/p38 signaling pathway in vitro and in vivo. This study provides novel insight into the effects of miR-21 on HB apoptosis and clue to develop new therapies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pathology, Linyi People's Hospital
Department of Infectious Diseases, Linyi People's Hospital
References (30)
Show source-provided references
1. 10.1053/j.sempedsurg.2011.10.01110.1053/j.sempedsurg.2011.10.011 ↗
2. Birch JM. Epidemiology of pediatric liver tumors, In Pediatric Liver Tumors. Berlin, Heidelberg: Springer; 2011. p. 15-26.
3. 10.1002/pbc.2421710.1002/pbc.24217 ↗
4. 10.1002/pbc.2274010.1002/pbc.22740 ↗
5. 10.2174/15665240978983912510.2174/156652409789839125 ↗
6. 10.1038/sj.onc.120990910.1038/sj.onc.1209909 ↗
7. 10.1073/pnas.090523410610.1073/pnas.0905234106 ↗
8. 10.1016/S1097-2765(01)00367-710.1016/S1097-2765(01)00367-7 ↗
9. 10.1080/104281902100004001710.1080/1042819021000040017 ↗
10. 10.1158/0008-5472.CAN-08-130510.1158/0008-5472.CAN-08-1305 ↗
11. 10.1007/s00247-006-0361-510.1007/s00247-006-0361-5 ↗
12. 10.7717/peerj-cs.6710.7717/peerj-cs.67 ↗
13. 10.1016/j.fct.2016.03.01310.1016/j.fct.2016.03.013 ↗
14. 10.1593/neo.12122210.1593/neo.121222 ↗
15. 10.1016/j.canlet.2014.08.02010.1016/j.canlet.2014.08.020 ↗
16. 10.18632/oncotarget.2473710.18632/oncotarget.24737 ↗
17. 10.1038/celldisc.2017.2210.1038/celldisc.2017.22 ↗
18. 10.1016/j.yexcr.2017.08.01110.1016/j.yexcr.2017.08.011 ↗
19. 10.1038/onc.2011.50010.1038/onc.2011.500 ↗
20. 10.1158/0008-5472.CAN-09-199610.1158/0008-5472.CAN-09-1996 ↗
21. 10.1158/0008-5472.CAN-05-013710.1158/0008-5472.CAN-05-0137 ↗
22. 10.1007/s00383-016-3960-810.1007/s00383-016-3960-8 ↗
23. 10.1007/s00428-014-1549-y10.1007/s00428-014-1549-y ↗
24. 10.1016/B978-0-08-046884-6.00223-210.1016/B978-0-08-046884-6.00223-2 ↗
25. 10.3390/ijms1602294210.3390/ijms16022942 ↗
26. 10.1186/bcr280310.1186/bcr2803 ↗
27. 10.5732/cjc.30.037110.5732/cjc.30.0371 ↗
28. 10.1016/j.tips.2004.01.00910.1016/j.tips.2004.01.009 ↗
29. 10.1007/s00432-004-0546-y10.1007/s00432-004-0546-y ↗
30. 10.1016/j.molcel.2004.11.02110.1016/j.molcel.2004.11.021 ↗